Canada Spends Logo

Explore our Budget 2026 analysis

Grant: SPOR Networks in Chronic Disease - LOI

University of British Columbia

$50,000.00

CaPITTAL: Canadian Patient-oriented Immune Tolerance in Transplantation and Autoimmunity to improve Lives

FY 2014-15

Summary
A functional immune system is essential for health. In a process called immune tolerance, it fends off dangerous foreign substances but leave the body's own tissues untouched. Failure of immune tolerance causes chronic autoimmune diseases (such as multiple sclerosis (MS), lupus, and diabetes) in which the immune system sees the body's own cells as foreign and attacks them. Transplant recipients, who must take medications to suppress their immune system, also live with an impaired immune tolerance. The chronic diseases caused by a lack of immune tolerance lower the quality of life of 2 million Canadians with autoimmune disease and 30,000 survivors of transplantation, and place a high demand on our health care system and economy. We need to move beyond symptom management and find ways to give patients desperately-needed long-term solutions. One exciting way is to develop treatments that re-set immune responses, restoring proper immune function. Towards this goal, the pan-Canadian network, CaPITTAL (Canadian Patient-oriented Immune Tolerance in Transplantation and Autoimmunity to improve Lives) will bring together researchers, physicians and patients, to conduct clinical trials of promising immune tolerance therapies, and ensure successful treatments become part of standard patient care. CaPITTAL will: (1) test experimental immune tolerance treatments in patients with autoimmunity and/or who have received a transplant; (2) develop personalized treatment approaches based on markers in the blood; and (3) study life-long complications to guide future research. Our initial focus will be immune tolerance in the context of transplantation (of organs and/or blood and marrow cells), Type 1 diabetes and MS, but results from these studies will be applicable to any condition for which a lack of immune intolerance is the underlying cause. Thus, CaPITTAL meets the CIHR SPOR Network priority of impact across numerous non-communicable chronic diseases with high disease burden.
Program
SPOR Networks in Chronic Disease - LOI
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
323878
Name
Schultz Kirk R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
SPOR Networks in Chronic Disease
Projecttitle
CaPITTAL: Canadian Patient-oriented Immune Tolerance in Transplantation and Autoimmunity to improve Lives
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
SPOR Networks in Chronic Disease - LOI
Keyworddelim
Biomarkers; Blood And Marrow Transplantation; Economic Impact Of Health Care; First In Human Clinical Trials; Immune Tolerance; Long Term Outcomes; Multiple Sclerosis; Patient Engagement; Solid Organ Transplantation; Type 1 Diabetes Mellitus
Abstract
A functional immune system is essential for health. In a process called immune tolerance, it fends off dangerous foreign substances but leave the body's own tissues untouched. Failure of immune tolerance causes chronic autoimmune diseases (such as multiple sclerosis (MS), lupus, and diabetes) in which the immune system sees the body's own cells as foreign and attacks them. Transplant recipients, who must take medications to suppress their immune system, also live with an impaired immune tolerance. The chronic diseases caused by a lack of immune tolerance lower the quality of life of 2 million Canadians with autoimmune disease and 30,000 survivors of transplantation, and place a high demand on our health care system and economy. We need to move beyond symptom management and find ways to give patients desperately-needed long-term solutions. One exciting way is to develop treatments that re-set immune responses, restoring proper immune function. Towards this goal, the pan-Canadian network, CaPITTAL (Canadian Patient-oriented Immune Tolerance in Transplantation and Autoimmunity to improve Lives) will bring together researchers, physicians and patients, to conduct clinical trials of promising immune tolerance therapies, and ensure successful treatments become part of standard patient care. CaPITTAL will: (1) test experimental immune tolerance treatments in patients with autoimmunity and/or who have received a transplant; (2) develop personalized treatment approaches based on markers in the blood; and (3) study life-long complications to guide future research. Our initial focus will be immune tolerance in the context of transplantation (of organs and/or blood and marrow cells), Type 1 diabetes and MS, but results from these studies will be applicable to any condition for which a lack of immune intolerance is the underlying cause. Thus, CaPITTAL meets the CIHR SPOR Network priority of impact across numerous non-communicable chronic diseases with high disease burden.
Competitiondate
201501
Approvedterm2
1 yr 0 mth
Pinamesdelim
Schultz, Kirk R; Tinckam, Kathryn J; Bar-Or, Amit; Keating, Armand; Levings, Megan K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~
University of British Columbia - $50,000 Grant (2014-… | Canada Spends